Lee W R, Hanks G E, Schultheiss T E, Corn B W, Hunt M A
Fox Chase Cancer Center, Department of Radiation Oncology, Philadelphia, PA 19111.
J Clin Oncol. 1995 Feb;13(2):464-9. doi: 10.1200/JCO.1995.13.2.464.
To determine the 5-year rate of survival with no evidence of disease (NED) using strict biochemical criteria in men with prostate cancer treated by external-beam radiotherapy alone and to examine possible clinical and treatment factors that predict the likelihood of NED survival.
Five hundred men with clinically localized prostate cancer consecutively treated with external-beam radiotherapy alone with no prior, concomitant, or adjuvant endocrine therapy were identified. All patients had serial serum prostate-specific antigen (PSA) values determined after treatment and 451 patients had pretreatment PSA values determined. The median follow-up duration is 20 months (range, 2 to 72; mean, 36).
The 5-year rate of overall survival in this group of patients was 80%. The 5-year rate of survival without clinical evidence of disease (cNED) was 72%. The 5-year rate of survival without evidence of clinical, radiographic, or biochemical relapse (bNED) was 51%. Multivariate analysis demonstrated that a pretreatment serum PSA level < or = 15 ng/mL was the most important predictor of bNED survival (P < .0001). Patients with early-stage (T1, T2a/b) tumors and a pretreatment serum PSA less than 15 ng/mL had a 3-year rate of bNED survival of 86%. The rate of bNED survival for patients with a pretreatment PSA level greater than 15 ng/mL was 38% at 3 years.
Pretreatment serum PSA level is the most important predictor of treatment outcome in this group of patients treated with definitive radiotherapy alone. External-beam radiation alone can produce acceptable early rates of bNED survival in patients with clinically organ-confined tumors and a pretreatment PSA level < or = 15 ng/mL. To produce acceptable results in those patients with pretreatment PSA levels more than 15 ng/mL, effective adjuvant treatments in addition to aggressive local treatments are necessary.
采用严格的生化标准确定单纯接受外照射放疗的前列腺癌男性患者5年无疾病证据(NED)生存率,并研究可能预测NED生存可能性的临床和治疗因素。
确定500例单纯接受外照射放疗、未接受过先前、同期或辅助内分泌治疗的临床局限性前列腺癌男性患者。所有患者在治疗后均测定了系列血清前列腺特异性抗原(PSA)值,451例患者测定了治疗前PSA值。中位随访时间为20个月(范围2至72个月;平均36个月)。
该组患者的5年总生存率为80%。无临床疾病证据(cNED)的5年生存率为72%。无临床、影像学或生化复发证据(bNED)的5年生存率为51%。多变量分析表明,治疗前血清PSA水平≤15 ng/mL是bNED生存的最重要预测因素(P<0.0001)。早期(T1、T2a/b)肿瘤且治疗前血清PSA低于15 ng/mL的患者3年bNED生存率为86%。治疗前PSA水平大于15 ng/mL的患者3年bNED生存率为38%。
在这组单纯接受根治性放疗的患者中,治疗前血清PSA水平是治疗结果的最重要预测因素。对于临床器官局限性肿瘤且治疗前PSA水平≤15 ng/mL的患者,单纯外照射放疗可产生可接受的早期bNED生存率。对于治疗前PSA水平大于15 ng/mL的患者,除积极的局部治疗外,还需要有效的辅助治疗才能产生可接受的结果。